Osteoblastic metastases in a patient with low-grade cohesive gastric carcinoma

Abstract

The article presents a clinical observation of osteoblastic metastases in a patient with poorly cohesive gastric carcinoma after several years of radical surgery. Multiple osteoblastic metastases sharply worsen the quality of life, adversely affect survival rate, and require timely comprehensive examination of patients with this pathology for early detection of “silent” bone metastases in order to improve long-term results of treatment.

Study objective: to describe a clinical case of osteoblastic metastases in poorly cohesive carcinoma.

Patient L., male, 48 years, was admitted to the RH#1 - NCM Therapy Department (Yakutsk, Russia) for examination with complaints of severe general weakness, severe pain in the hip joints and both lower extremities, sacrum, intensifying during walking and lying down, decreased appetite, dyssomnia due to pain syndrome.

In the Therapy Department the patient underwent CBC, biochemical analysis of blood, instrumental research. He received symptomatic treatment: table 5 diet, Nutriflex 40/80 intravenously. for parenteral nutrition, omeprazole with an antiulcer purpose, tramadol 2.0 ml and diclofenac 3.0 ml for pain control, vitamins B12 200 mcg per day, ketotifen 1 mg 1 time in the evening with a sedation. The condition is unchanged, the expressed pain syndrome in the hip joints and sacrum remains.

The patient was discharged with recommendations and referred to the Yakutsk Republican Oncological Dispensary to an oncologist and a chemotherapist for the selection of effective analgesic drug therapy and possible local radiation therapy.

Conclusion. Poorly cohesive gastric carcinoma is often diagnosed at late stages and has a poor prognosis. Our clinical case demonstrates that this form of cancer can be a source of multiple osteoblastic metastases, which drastically worsens the quality of life and adversely affects survival rate, and requires a timely comprehensive examination of patients with this pathology for early detection of “silent” bone metastases in order to improve long-term treatment results.